Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial...

We are excited to announce that an Investigational New Drug (IND) application for WBP216 (MEDI5117), a novel anti-IL-6 antibody for rheumatoid arthritis (RA) and other autoimmune disorders – developed by our...

WuXi AppTec Receives Inaugural “Company of the Year” Award from BayHelix

We are honored to announce that WuXi has received the inaugural “Company of the Year” Award from BayHelix. The award is part of the BayHelix China Healthcare Awards series, celebrating outstanding...

WuXi’s STA Biotech CMC Outsourcing Boston Symposium Recap

WuXi’s STA Pharmaceutical recently hosted a knowledge sharing and networking symposium, “Biotech CMC Outsourcing Strategies – Boston.” More than 100 industry CMC professionals and collaborators participated in this event, which focused...

WuXi’s STA Leaders Provide Industry Trends and Insights During CPhI Worldwide 2016

More than 36,000 pharma professionals from over 150 countries attended the CPhI Worldwide 2016 convention in Barcelona Spain earlier this month to stay updated on the latest industry trends, meet with global...

WuXi AppTec Unveils Manufacturing Center for Cutting Edge Cell and Gene Therapies

We are thrilled to announce the grand opening of our Center for Clinical and Commercial Manufacturing of Advanced Therapies in the Philadelphia Navy Yard. The 150,000 square foot biomanufacturing facility is designed...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS